Monte Rosa Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Pipeline and Business Progress
Retrieved on:
Thursday, August 12, 2021
Protein, GSPT1, Conference, Program, Inflammasome, Air Force Legal Operations Agency, Administration, GLOBE, Head, Seaport District, Â, Private Securities Litigation Reform Act, Cancer, MGD, Public expenditure, NASDAQ, CEO, Biodata, IND, Precision medicine, CEST, N-Myc, Research and development, IPO, Myc, Company, Genomics, U.S. Securities and Exchange Commission, Research, Finance, Horizon, EDT, NLRP3, G&A, Exercise, R, COVID-19, Therapy, Proteomics, Completeness, Security (finance), Pharmaceutical industry, Fine chemical, Vaccine, Lithium
BOSTON, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue precision medicines, today reported business highlights and financial results for the second quarter, ended June 30, 2021.
Key Points:
- Research and Development (R&D) Expenses: R&D expenses for the second quarter of 2021 were$14.6 million, compared to $4.9 million for the second quarter of 2020.
- General and Administrative (G&A) Expenses: G&A expenses for the second quarter of 2021 were $3.5 million, compared to $0.5 million for the second quarter of 2020.
- Net Loss: Net loss for the second quarter of 2021 was $18.4 million, compared to $5.4 million for the second quarter of 2020.
- Monte Rosa Therapeutics is a biotechnology company developing a portfolio of novel molecular glue degrader precision medicines.